Biomarker results from a phase II study of MEK1/2 inhibitor...

Oncotarget 2019 / 03 Vol. 10; Iss. 19

Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanoma

van Herpen, Carla M.L., Agarwala, Sanjiv S., Hauschild, Axel, Berking, Carola, Beck, J. Thaddeus, Schadendorf, Dirk, Jansen, Rob, Queirolo, Paola, Ascierto, Paolo A., Blank, Christian U., Heinrich, Mi
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
10
Language:
english
Journal:
Oncotarget
DOI:
10.18632/oncotarget.26753
Date:
March, 2019
File:
PDF, 2.35 MB
english, 2019
Conversion to is in progress
Conversion to is failed